On an earnings call with analysts this week, Boston Scientific (NYSE:BSX) CEO Mike Mahoney touted the momentum of his company’s drug-eluting stent portfolio but noted that the technologies continue to face headwinds in the U.S. thanks to pricing pressure.
The Mass.-based company reported third-quarter profits of $432 million, or 31¢ per share, on sales of $2.39 billion for the three months ended Sept. 30, for a bottom-line gain of 52.7% on sales growth of 7.7% compared with Q3 2017.
Get the full story at our sister site, Drug Delivery Business News.
The post Boston Scientific CEO talks pricing pressure for drug-eluting stents appeared first on MassDevice.
from MassDevice https://ift.tt/2D5qa0m
Cap comentari:
Publica un comentari a l'entrada